1/10
Looks like no tags are added yet.
What is the clinical challenge with tumors
How do we enhance immunity
What is the clinical challenge of transplants
How to suppress immune response to grafts
What is the primary cell type common between tumor and transplants responses.
CTLs which attempt to destroy both because they are identified as foreign
Describe tumor antigens
Malignant tumors express various types of molecules that my be recognized as foreign
But it is a sloppy response because immune system can’t decide how “strong” of a response to induce
Who fights against tumor cell killing
NK cells and Activated macrophages via ADCC
Activated cytotoxic cells via CTLs/APCs
Immune mechanisms of tumor rejection or destruction
Principal mechanics involves killing of tumors by CTLs specific to tumor antigens. (cross presentation)
NK cells: ADCC and lysis
Macrophages: produce inflammatory cytokines and ADCC

Describe evasion of immune responses to tumors
Tumors stop expressing antigens
Tumors stop expressing MHCs
Immune response suppression: cytokines, CTLA-4, Tregs
Transfer of autologous T cells for enhancing anti-tumor immune responses
T cells removed from patients blood and expanded in vitro and then put back in
Monoclonal antibodies specific for tumor antigen put back into patient
Results in CMI or Antibody mediated killing of tumor
Describe DC vaccines for enhancing anti-tumor immune responses
DC with tumors antigens are administer to patient
Tumor antigens presented to T cells removed
T cell activation
Describe Tumor immunotherapy immune checkpoint blockade
If native T cells bind with PD-1 it results normal inhibition of CMI but if Anit - PD-1 is administered it initiates CMI respones on tumors
Similar to what takes place with DCs and CTLA-4 binding in lymphoid tissues.